Prevalence, treatment, and 1-year outcomes of heart failure with mid-range ejection fraction

Background: The prevalence of patients with heart failure mid-range ejection fraction (HFmrEF) remains unchanged regardless healthcare strategies. HFmrEF has mixed characteristics preserved (HFpEF) and reduced (HFrEF). treatment was recommended to be similar the HFpEF in 2016 guidelines European Society Cardiology (ESC) but changed those HFrEF 2021 version. Objective: To describe clinical inpatients a focus on practices. Methods: A prospective study conducted diagnosed who were admitted cardiology department Nhan Dan Gia Dinh hospital from July 2019 2020. Rehospitalization mortality followed up by telephone after 1 year. Results: Of total 529 cases during period, there 73 (13.8%) HFmrEF. mean age 68 years males comprised 53%. average hospitalization stay length 6.7 days. most common precipitating factors non-adherence (42.5%) infection (39.7%) hypertensive crisis (8.2%), anemia (6.8%), acute myocardial infarction (5.5%), arrhythmia (4.1%), hyperthyroidism (2.7%). Ischemic disease leading cause (61.6%) HFmrEF, hypertension (12.3%). rates treated beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, aldosterone antagonists 76.1%, 76.71%, 37.73%, 47.95%, respectively. There no statistically significant differences guideline-directed medical therapy (GDMT) medications administered between due ischemic non-ischemic causes. After 1-year follow-up, combined outcome rehospitalization 24.7%. Conclusion: that 2020 at accordance ESC guidelines.